tetano
Editor, Senior Moderator
J Infect Dis
. 2024 Sep 16:jiae454.
doi: 10.1093/infdis/jiae454. Online ahead of print. Immunogenicity and Reactogenicity of High-dose or Standard-dose Influenza Vaccine in a Second Consecutive Influenza Season
Hannah Bahakel[SUP] 1 [/SUP], Andrew J Spieker[SUP] 2 [/SUP], Haya Hayek[SUP] 3 [/SUP], Jennifer E Schuster[SUP] 4 [/SUP], Lubna Hamdan[SUP] 1 [/SUP], Daniel E Dulek[SUP] 3 [/SUP], Carrie L Kitko[SUP] 3 [/SUP], Tess Stopczynski[SUP] 2 [/SUP], Einas Batarseh[SUP] 3 [/SUP], Zaid Haddadin[SUP] 3 [/SUP], Laura S Stewart[SUP] 3 [/SUP], Anna Stahl[SUP] 3 [/SUP], Molly Potter[SUP] 3 [/SUP], Herdi Rahman[SUP] 3 [/SUP], Justin Amarin[SUP] 3 [/SUP], Spyros A Kalams[SUP] 3 [/SUP], Claire E Bocchini[SUP] 5 [/SUP], Elizabeth A Moulton[SUP] 5 [/SUP], Susan E Coffin[SUP] 6 [/SUP], Monica I Ardura[SUP] 7 [/SUP], Rachel L Wattier[SUP] 8 [/SUP], Gabriela Maron[SUP] 9 [/SUP], Michael Grimley[SUP] 1 [/SUP], Grant Paulsen[SUP] 1 [/SUP], Christopher J Harrison[SUP] 4 [/SUP], Jason Freedman[SUP] 6 [/SUP], Paul A Carpenter[SUP] 10 [/SUP], Janet A Englund[SUP] 10 [/SUP], Flor M Munoz[SUP] 5 [/SUP], Lara Danziger-Isakov[SUP] 1 [/SUP], Natasha Halasa[SUP] 2 [/SUP]; Pediatric HCT Flu Study
Collaborators, Affiliations
Background: Pediatric hematopoietic cell transplant (HCT) recipients are at high-risk for morbidity from influenza virus infection. We demonstrated in a primary phase II randomized controlled trial that two post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given four weeks apart were more immunogenic than two doses of standard-dose quadrivalent influenza vaccine (SD-QIV). Herein, we present immunogenicity and safety of influenza vaccination in a consecutive season post-HCT using the same dosing regimen.
Methods: A subcohort of study participants re-enrolled and had hemagglutinin inhibition (HAI) titers measured at baseline and four weeks after each vaccine dose in year two. We estimated geometric mean fold rise (GMFR) in HAI titer from baseline for each group and used linear mixed effects models to estimate adjusted geometric mean ratios (aGMR, comparing HD-TIV to SD-QIV) for each antigen at each time point. We described systemic and injection-site reactions.
Results: A total of 65 subcohort patients participated (33 SD-QIV, 32 HD-TIV). Post-vaccine GMFR and aGMR estimates were higher for both groups following a single influenza vaccine dose in year two compared to two doses of the same formulation in year one. Both groups had similar frequencies of injection-site and systemic reactions.
Conclusions: A single dose of HD-TIV or SD-QIV was more immunogenic in year two than two doses of the same formulation in year one. Reactogenicity was comparable between groups. One dose of influenza vaccine may be sufficient after a two-dose schedule in the prior year post-HCT.
Keywords: high dose; influenza; pediatrics; stem cell recipients; vaccination.
. 2024 Sep 16:jiae454.
doi: 10.1093/infdis/jiae454. Online ahead of print. Immunogenicity and Reactogenicity of High-dose or Standard-dose Influenza Vaccine in a Second Consecutive Influenza Season
Hannah Bahakel[SUP] 1 [/SUP], Andrew J Spieker[SUP] 2 [/SUP], Haya Hayek[SUP] 3 [/SUP], Jennifer E Schuster[SUP] 4 [/SUP], Lubna Hamdan[SUP] 1 [/SUP], Daniel E Dulek[SUP] 3 [/SUP], Carrie L Kitko[SUP] 3 [/SUP], Tess Stopczynski[SUP] 2 [/SUP], Einas Batarseh[SUP] 3 [/SUP], Zaid Haddadin[SUP] 3 [/SUP], Laura S Stewart[SUP] 3 [/SUP], Anna Stahl[SUP] 3 [/SUP], Molly Potter[SUP] 3 [/SUP], Herdi Rahman[SUP] 3 [/SUP], Justin Amarin[SUP] 3 [/SUP], Spyros A Kalams[SUP] 3 [/SUP], Claire E Bocchini[SUP] 5 [/SUP], Elizabeth A Moulton[SUP] 5 [/SUP], Susan E Coffin[SUP] 6 [/SUP], Monica I Ardura[SUP] 7 [/SUP], Rachel L Wattier[SUP] 8 [/SUP], Gabriela Maron[SUP] 9 [/SUP], Michael Grimley[SUP] 1 [/SUP], Grant Paulsen[SUP] 1 [/SUP], Christopher J Harrison[SUP] 4 [/SUP], Jason Freedman[SUP] 6 [/SUP], Paul A Carpenter[SUP] 10 [/SUP], Janet A Englund[SUP] 10 [/SUP], Flor M Munoz[SUP] 5 [/SUP], Lara Danziger-Isakov[SUP] 1 [/SUP], Natasha Halasa[SUP] 2 [/SUP]; Pediatric HCT Flu Study
Collaborators, Affiliations
- PMID: 39279435
- DOI: 10.1093/infdis/jiae454
Background: Pediatric hematopoietic cell transplant (HCT) recipients are at high-risk for morbidity from influenza virus infection. We demonstrated in a primary phase II randomized controlled trial that two post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given four weeks apart were more immunogenic than two doses of standard-dose quadrivalent influenza vaccine (SD-QIV). Herein, we present immunogenicity and safety of influenza vaccination in a consecutive season post-HCT using the same dosing regimen.
Methods: A subcohort of study participants re-enrolled and had hemagglutinin inhibition (HAI) titers measured at baseline and four weeks after each vaccine dose in year two. We estimated geometric mean fold rise (GMFR) in HAI titer from baseline for each group and used linear mixed effects models to estimate adjusted geometric mean ratios (aGMR, comparing HD-TIV to SD-QIV) for each antigen at each time point. We described systemic and injection-site reactions.
Results: A total of 65 subcohort patients participated (33 SD-QIV, 32 HD-TIV). Post-vaccine GMFR and aGMR estimates were higher for both groups following a single influenza vaccine dose in year two compared to two doses of the same formulation in year one. Both groups had similar frequencies of injection-site and systemic reactions.
Conclusions: A single dose of HD-TIV or SD-QIV was more immunogenic in year two than two doses of the same formulation in year one. Reactogenicity was comparable between groups. One dose of influenza vaccine may be sufficient after a two-dose schedule in the prior year post-HCT.
Keywords: high dose; influenza; pediatrics; stem cell recipients; vaccination.